Clinical Trial Update: Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Samarium-153 Lexidronam Pentasodium with 3D-conformal radiotherapy or intensity-modulated radiotherapy in patients with rising PSA afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Quadramet (samarium-153 lexidronam pentasodium)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-07-25